A large pool of evidence exists to support the use of HIPEC in ovarian cancer, and hyperthermic and other novel intraperitoneal chemotherapies should continue to be incorporated into novel clinical trial designs.
Thanh H. Dellinger, MD
Advertisement
Articles by Thanh H. Dellinger, MD
Advertisement
Latest Updated Articles
Growing Body of Evidence Supports Use of HIPEC in Ovarian CancerSeptember 18th 2019
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL
5